[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642090":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":33,"studyPopulation":26,"armGroups":34,"interventions":45,"overallOfficials":26,"centralContacts":26,"locations":55,"responsibleParty":84,"collaborators":26,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":26,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":26,"enrollmentInfo":96,"targetDuration":26,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":57,"whyStopped":26,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Bangladesh Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"Pain intensity reduction as measured by the Visual Analog Scale (VAS)","This measure evaluates the effectiveness of Neurolytic Splanchnic Nerve Block (NSNB) compared to Neurolytic Coeliac Plexus Block (NCPB) in reducing pain in patients with upper abdominal malignancies. Zero indicates no pain, and 10 indicates the worst possible pain.","Baseline, Immediately after the intervention, at 7 days, 1 month, and 3 months post-procedure",[14,18,22],{"measure":15,"description":16,"timeFrame":17},"Opioid Consumption","This measures whether the intervention reduces the need for systemic opioids.","Baseline, Day 7, 1 month, and 3 months post-procedure.",{"measure":19,"description":20,"timeFrame":21},"Quality of Life using scores from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)","This assesses functional, symptom, and global health aspects of patient well-being following nerve block interventions. Scores range from 0 to 100. Higher scores indicate better global health and functioning, while higher symptom scores indicate worse symptoms.","Baseline, 1 month and 3 months post-procedure.",{"measure":23,"description":24,"timeFrame":25},"Incidence of immediate or delayed complications, including hypotension, diarrhea, back pain, shoulder pain, pneumothorax, or neurological changes.","This evaluates the safety profile of NSNB compared to NCPB","Immediately post-procedure and during follow-up visits up to 3 months.",null,{"allocation":28,"interventionModel":29,"interventionModelDescription":26,"primaryPurpose":30,"observationalModel":26,"timePerspective":26,"maskingInfo":31},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":32,"maskingDescription":26,"whoMasked":26},"NONE","This study is a quasi-experimental, interventional trial conducted at the Division of Pain Medicine \\& Regional Anaesthesia, Department of Anaesthesia, Analgesia and Intensive Care Medicine, Bangladesh Medical University, Dhaka. Adult patients diagnosed with upper abdominal malignancies (including pancreatic, gastric, hepatic, or biliary origin) who report moderate to severe pain (VAS ≥5) and have no contraindications for nerve blocks will be enrolled.\n\nEligible participants will be allocated in a 1:1 ratio into two groups. The control group will receive a fluoroscopy-guided Neurolytic Coeliac Plexus Block (NCPB). The procedure involves patient positioning in the prone posture with abdominal flexion, identification of anatomical landmark L1 under posteroanterior and oblique C-arm fluoroscopy, skin infiltration with local anesthetic, and injection of 3 mL 0.25% bupivacaine, followed by 20 mL of 70% alcohol for neurolysis, with 1 mL saline flush during needle withdrawal to prevent tract formation. The study group will receive a fluoroscopy-guided Neurolytic Splanchnic Nerve Block (NSNB) using a similar approach, with needle placement at the T11-T12 level, 3 mL of local anesthetic, and 10 mL of 70% alcohol for neurolysis.\n\nBaseline evaluations will include a complete blood count, a coagulation profile (prothrombin time, bleeding time, clotting time, INR), a Visual Analog Scale (VAS) pain score, and a quality-of-life assessment using the EORTC QLQ-C30. Participants will be monitored immediately and for 2 hours post-procedure for complications, including hypotension, diarrhea, back or shoulder pain, pneumothorax, or neurological changes.\n\nFollow-up assessments will occur immediately post-procedure, at 7 days, 1 month, and 3 months. Pain intensity, opioid consumption, and quality-of-life scores will be recorded.\n\nThis study aims to provide comparative data on analgesic efficacy, opioid-sparing effects, safety, and quality-of-life outcomes between NCPB and NSNB in patients with upper abdominal malignancies.",[35,40],{"label":36,"type":37,"description":26,"interventionNames":38},"Control group","ACTIVE_COMPARATOR",[39],"Procedure: Neurolytic Coeliac Plexus Block (NCPB)",{"label":41,"type":42,"description":26,"interventionNames":43},"Intervention Group","EXPERIMENTAL",[44],"Procedure: Neurolytic Splanchnic Nerve Block (NSNB)",[46,51],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":26},"PROCEDURE","Neurolytic Coeliac Plexus Block (NCPB)","Fluoroscopy-guided neurolytic coeliac plexus block performed on adult patients with upper abdominal malignancies. Patients are positioned prone with a pillow under the abdomen. Using posteroanterior and oblique C-arm fluoroscopy, the T12-L1 vertebral bodies are identified. After local anesthetic infiltration, 3 mL of 0.25% bupivacaine is injected, followed by 20 mL of 70% alcohol for neurolysis. A 1 mL saline flush is given during needle withdrawal to prevent track formation. Patients are monitored immediately and for 2 hours post-procedure for adverse effects including hypotension, diarrhea, back pain, shoulder pain, or neurological changes.",[36],{"type":47,"name":52,"description":53,"armGroupLabels":54,"otherNames":26},"Neurolytic Splanchnic Nerve Block (NSNB)","Fluoroscopy-guided neurolytic splanchnic nerve block performed in adults with upper abdominal malignancies. Patients are positioned prone with proper support. Using posteroanterior and lateral C-arm fluoroscopy, T11-T12 vertebral bodies and the junction of the rib and vertebral body are identified. After local anesthetic infiltration, a Chiba needle is advanced to the anterior one-third of the lateral vertebral body. Contrast dye is injected to confirm placement. Neurolysis is performed using 10 mL of 70% alcohol, preceded by 2-3 mL of 0.25% bupivacaine. A 1 mL saline flush is given during needle withdrawal to prevent track formation. Patients are monitored immediately and for 2 hours post-procedure for complications including hypotension, diarrhea, back pain, shoulder pain, pneumothorax, or neurological changes.",[41],[56],{"facility":5,"status":57,"city":58,"state":26,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Dhaka","1000","Bangladesh","BD",{"type":63,"coordinates":64},"Point",[65,66],90.40744,23.7104,{"lat":66,"lon":65},[69,74,77,80,82],{"name":70,"role":71,"phone":72,"phoneExt":26,"email":73},"Kazi Mahzabin Arin, MD","CONTACT","+8801754057689","kazimahzabinarin@bsmmu.edu.bd",{"name":75,"role":71,"phone":26,"phoneExt":26,"email":76},"AKM Akhtaruzzaman, MD","akhtaruzzaman.akm@bmu.ac.bd",{"name":78,"role":79,"phone":26,"phoneExt":26,"email":26},"Nadia Sultana, MD","PRINCIPAL_INVESTIGATOR",{"name":70,"role":81,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"name":83,"role":81,"phone":26,"phoneExt":26,"email":26},"Md Mostafa Kamal, MD",{"type":79,"investigatorFullName":85,"investigatorTitle":86,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Kazi Mahzabin Arin","Assistant Professor","100642090","coeliac-plexus-vs-splanchnic-nerve-neurolysis-for-upper-abdominal-cancer-pain-100642090",false,"NCT07653906","Coeliac Plexus vs Splanchnic Nerve Neurolysis for Upper Abdominal Cancer Pain","Effect of Coeliac Plexus Versus Splanchnic Nerve Neurolysis in Pain Management With Upper Abdominal Malignancies","Inclusion Criteria:\n\n* Adult patient\n* Both genders\n* Diagnosed case of upper abdominal malignancy (pancreatic, gastric, hepatic, or biliary origin)\n* Experiencing moderate to severe pain (≥5 on a 10 point visual analog scale)\n* Patients who are conscious and can communicate\n* No Contraindication for nerve block (e.g., coagulopathy, anticoagulant drugs)\n\nExclusion Criteria:\n\n* Previous coeliac plexus block, splanchnic nerve block, or major abdominal nerve ablation\n* Severe spinal deformities or anatomical distortion at the coeliac plexus or splanchnic nerve site\n* Local or systemic infection at or near the block site\n* Known allergy to local anesthetics or neurolytic agents\n* Pregnancy\n* Lactating mother\n* Cognitive impairment or psychiatric illness","ALL","18 Years",{"count":97,"type":98},44,"ESTIMATED","INTERVENTIONAL",[101],"NA","The goal of this clinical trial is to determine whether Neurolytic Splanchnic Nerve Block (NSNB) reduces pain in adults with upper abdominal malignancies. It will also evaluate the safety of Neurolytic Splanchnic Nerve Block (NSNB). The main questions it aims to answer are:\n\nDoes NSNB reduce pain intensity compared to Neurolytic Coeliac Plexus Block (NCPB), as measured by the Visual Analog Scale (VAS)? What adverse effects do participants experience when receiving Neurolytic Splanchnic Nerve Block (NSNB)?\n\nInvestigators will compare Neurolytic Splanchnic Nerve Block (NSNB) with Neurolytic Coeliac Plexus Block (NCPB) to determine which intervention provides more effective and safer pain relief.\n\nParticipants will:\n\n* receive either NSNB or NCPB under fluoroscopic guidance\n* be monitored immediately and for 2 hours after the procedure for any complications Have their pain intensity recorded immediately after the procedure, and at 7 days, 1 month, and 3 months\n* be evaluated for quality-of-life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 3 (EORTC QLQ-C30) at 1 month and 3 months.\n* have their opioid consumption tracked throughout the study.",[104,105,106],"Abdominal Neoplasms","Pain Management","Neurolytic Techniques",[108,109,110,111],"Upper abdominal cancer","Splanchnic nerve block","Coeliac plexus block","Analgesic efficacy","2026-06-12",{"date":114,"type":115},"2026-06-17","ACTUAL",{"date":117,"type":115},"2026-05-01",{"date":119,"type":98},"2027-01-31",{"name":5,"class":6},1]